Aktienanalyse zu ImmuCell Corp (ICCC)ICCCImmuCell Corp

ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus). It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

ImmuCell Corp is a good buy right now due to its recent strong performance, including a 78.38% year-to-date change and a current price of $10.56, which is 79.7% of its 52-week range. The RSI is at 59.55, indicating a healthy momentum, while the gross margin stands at 33.92%, showing profitability despite some recent declines. The main risk is the drop in international sales by 38.9%, which could impact future growth.